TheraRadar
← Back
Data updated: Nov 8, 2026

Biogen

BIIB Biotech
NeurologyImmunologyMetabolic Execution: Good

Neuroscience-focused biotech with MS portfolio (Tecfidera, Tysabri) and controversial Alzheimer's drug Leqembi. Pioneer in neurological diseases.

$9.8B
Revenue (2024)
$22.0B
Market Cap
-
Trials
0
New Drugs (2yr)
Modality:
6 Small Molecules 5 Biologics

FDA Novel Drug Designations

(2016-2023)
6 Novel 4 First-in-Class 3 Orphan 2 Accelerated 6 Priority Review 5 Fast Track
See 6 novel approvals →
2023 QALSODY (TOFERSEN) First-in-Class · Orphan · Priority Review · Accelerated · Fast Track
2023 SKYCLARYS (OMAVELOXOLONE) First-in-Class · Orphan · Priority Review · Fast Track
2023 ZURZUVAE (ZURANOLONE) Priority Review · Fast Track
2021 ADUHELM (ADUCANUMAB-AVWA) First-in-Class · Priority Review · Accelerated · Fast Track
2016 SPINRAZA (NUSINERSEN SODIUM) First-in-Class · Orphan · Priority Review · Fast Track
2016 ZINBRYTA (DACLIZUMAB) Priority Review

Biogen at a Glance

  • Leading 5 drug targets across portfolio
  • Fast trial execution (16 months median completion)

Biogen's Recent FDA Approvals

New NDA/BLA approvals for Biogen over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Biogen's Therapeutic Areas

Biogen's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Immunology, across 5 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 73%
5 drugs Phase 3: 37 Phase 2: 24 Phase 1: 44
Immunology 13%
2 drugs Phase 3: 4 Phase 2: 7 Phase 1: 4
Metabolic 5%
0 drugs Phase 3: 1 Phase 2: 6 Phase 1: 3
Oncology 5%
0 drugs Phase 2: 3 Phase 1: 11
Cardiovascular 4%
0 drugs Phase 3: 3 Phase 2: 2

Biogen's Top Competitors

Biogen's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Sanofi big-pharma
Metabolic, Oncology, Immunology, Cardiovascular
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Roche big-pharma
Oncology, Immunology, Neurology, Metabolic
AstraZeneca big-pharma
Oncology, Metabolic, Cardiovascular, Immunology
Pfizer big-pharma
Oncology, Immunology, Neurology

Biogen Pipeline Snapshot

Biogen has 149 active clinical programs from ClinicalTrials.gov — 45 Phase 3, 42 Phase 2 and 62 Phase 1.

45
Phase 3
42
Phase 2
62
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Felzartamab
Antibody-mediated Rejection
Estimated · aging NCT06685757
Q2 2027
BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Estimated · stale NCT03958877
Q2 2027
Felzartamab
Immunoglobulin A Nephropathy (IgAN)
Estimated · aging NCT06935357
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • SPINRAZA leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Neurology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 34/76 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges